Abstracts Archive - Page 157 of 2607 - ACR Meeting Abstracts

Abstract Number: 0523 • ACR Convergence 2025
SPECTREM: Guselkumab Significantly Improves Patient Reported Outcomes at Week 16 in Participants with Low Body Surface Area, Moderate Psoriasis with Special Sites Involvement
Jennifer Soung¹, Virginie Kelly², Marni Wiseman³, Adrian Rodriguez⁴, Theodore Alkousakis⁵, Olivia Choi⁵, Daphne Chan⁵, Katelyn Rowland⁵, Linda Hou⁶, Jenny Jeyarajah⁷, Nastaran Abbarin⁸, Elizabeth Skobelev⁵, Sancharitha Ramji⁵, James Krell⁹, Max Sauder¹⁰ and David Adam¹¹, ¹Southern California Dermatology, Inc, Santa Ana, CA, USA, Santa Ana, ²Saint-Louis Medical Clinic, Quebec, Canada, Quebec, Canada, ³SkinWise Dermatology, Manitoba, Canada, Manitoba, Canada, ⁴Nashville Skin Comprehensive Dermatology Center, Nashville, TN, USA, Nashville, TN, ⁵Johnson & Johnson, Horsham, PA, USA, Horsham, PA, ⁶Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, ⁷Johnson & Johnson, Horsham, PA, USA, Horsham, ⁸Janssen Inc, Toronto, ON, Canada, Toronto, Canada, ⁹Total Skin & Beauty Dermatology Center, Birmingham, AL, USA, Birmingham, ¹⁰Probity Medical Research, ON, Canada; University of Toronto, ON, Canada, Toronto, Canada, ¹¹CCA Medical Research, ON, Canada, Toronto, Canada
Background/Purpose: Even low body surface area (BSA) psoriasis can be extremely bothersome to patients and can have a significant impact on their lives just as…
Abstract Number: 0850 • ACR Convergence 2025
Single-cell RNA-seq analysis of synovial CD4+ T cells identifies a novel biomarker and therapeutic target in human rheumatoid arthritis
Akinori Murakami¹, Rinko Akamine¹, Koichi Murata¹, Kohei Nishitani¹, Hiromu Ito², Ryu Watanabe³, Takayuki Fujii¹, Takeshi Iwasaki¹, Yuki Masuo⁴, Osamu Iri¹, Shinichiro Nakamura¹, Shinichi Kuriyama¹, Yugo Morita¹, Yasuhiro Murakawa⁵, Chikashi Terao⁶, Yukinori Okada⁷, Motomu Hashimoto³, Shuichi Matsuda¹, Hideki Ueno¹ and Hiroyuki Yoshitomi¹, ¹Kyoto University, Kyoto, Japan, ²Kyoto University / Kurashiki Central Hospital, Kyoto, Japan, ³Osaka Metropolitan University, Osaka, Japan, ⁴Graduate school of medicine, Kyoto University, Kyoto, Japan, ⁵Kyoto University / RIKEN, Kyoto, Japan, ⁶RIKEN, Tokyo, Japan, ⁷The University of Tokyo / Osaka University / RIKEN, Tokyo, Japan
Background/Purpose: CD4+ T cells play a central role in the pathogenesis of human rheumatoid arthritis (RA). However, therapies targeting CD4+ T cell-derived humoral factors, including…
Abstract Number: 0842 • ACR Convergence 2025
Association of urinary biomarkers with histological features in diagnostic and per-protocol repeat kidney biopsies in lupus nephritis
Andrea Fava¹, CHEN-YU LEE¹, Carla Guthridge², Dionysis Nikolopoulos³, Julius Lindblom⁴, Farah Tamirou⁵, Michelle Petri⁶, Joel Guthridge², Frederic Houssiau⁷ and Ioannis Parodis⁸, ¹Johns Hopkins University, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Cliniques universitaires Saint-Luc, Brussels, Belgium, ⁶Johns Hopkins University School of Medicine, Timonium, MD, ⁷CUSL, BRUSSELS, Belgium, ⁸Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden
Background/Purpose: Persistent intrarenal inflammation despite immunosuppression drives kidney damage and functional decline in lupus nephritis (LN). Yet, current guidelines do not recommend repeat biopsy to…
Abstract Number: 0775 • ACR Convergence 2025
Increased Circulating Microbial Small RNA tDR-1 is Associated with Decreased Progression to Future Clinical Rheumatoid Arthritis In High Risk Individuals and Reduces In Vitro Type 1 Interferon Response Gene Expression
Anastasiia Phothisane¹, Tulsi Joishy², Carolina Ramirez-Becerra¹, Zuofei Wang², Qiong Wu³, Jennifer Seifert⁴, Marie Feser⁵, Jill Norris⁶, Kristen Demoruelle⁷, LauraKay Moss⁵, Kevin Deane⁸, V. Michael Holers⁹ and Michelle Ormseth², ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, ³University of Virginia, Charlottesville, VA, ⁴University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ⁵University of Colorado Anschutz Medical Campus, Aurora, CO, ⁶Colorado School of Public Health, Denver, CO, ⁷University of Colorado Anschutz Medical Campus, Golden, CO, ⁸University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁹University of Colorado Anschutz Medical Campus, Aurora
Background/Purpose: Microbial small RNAs (sRNAs) can regulate human genes, often with anti-inflammatory effects. We previously showed that an increased plasma concentration of a tRNA-derived RNA…
Abstract Number: 0846 • ACR Convergence 2025
A Longitudinal Transcriptomic Study of Mycophenolate Mofetil in Systemic Sclerosis Skin with Clinical and Molecular Stratification
Rezvan Parvizi¹, Zhiyun Gong², Natania Field³, Helen Jarnagin², Dillon Popovich², Monica Yang⁴, Kathleen Aren⁵, Mary Carns⁶, Isaac Goldberg⁷, Lorinda Chung⁸, Vivien Goh⁹, Zsuzsanna McMahan¹⁰, Tammara Wood¹¹, Dinesh Khanna¹², Monique Hinchcliff¹³ and Michael Whitfield¹⁴, ¹Dartmouth, lebanon, NH, ²Dartmouth College, Lebanon, NH, ³Northwestern Memorial Hospital, Chicago, IL, ⁴UCSF, San Francisco, CA, ⁵Northwestern University Division of Rheumatology, Chicago, IL, ⁶Northwestern University, Chicago, IL, ⁷Wayne State University, Detroit, ⁸Stanford University, Stanford, CA, ⁹Northwestern, Chicago, ¹⁰UT Health Houston, Houston, TX, ¹¹Dartmouth, Hanover, NH, ¹²University of Michigan, Ann Arbor, MI, ¹³Yale School of Medicine, Westport, CT, ¹⁴Geisel School of Medicine, Lebanon, NH
Background/Purpose: Mycophenolate Mofetil (MMF) is the most commonly prescribed immunosuppressive treatment for patients diagnosed with diffuse cutaneous systemic sclerosis (dcSSc). Here, we analyzed skin gene…
Abstract Number: 0736 • ACR Convergence 2025
Effectiveness of Tocilizumab in strokes in patients with giant cell arteritis. Spanish multicenter study of clinical practice
Ana Serrano-Combarro¹, Javier Loricera², Clara Moriano³, Santos Castañeda⁴, Javier Narváez⁵, Vicente Aldasoro Cáceres⁶, Rafael B. Melero-González⁷, Isabel De la Morena⁸, Ivan Ferraz Amaro⁹ and Ricardo Blanco¹⁰, ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Hospital León, LEON, Castilla y Leon, Spain, ⁴Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Navarra, Pamplona, Spain, ⁷COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ⁸HOSPITAL CLINICO UNIVERSITARIO DE VALENCIA, VALENCIA, Spain, ⁹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁰Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Stroke is a feared complication of giant cell arteritis (GCA). Tocilizumab (TCZ) has shown efficacy and safety in large-vessel vasculitis (LVV) including GCA. Our…
Abstract Number: 0531 • ACR Convergence 2025
Evaluating the Diagnostic Utility of 14-3-3 eta Autoantibodies in Axial Spondyloarthritis: A Multiplex Assay Approach
Anthony Marotta¹, Walter P. Maksymowych², Stephen Bleakley¹, Stephanie Wichuk³ and Norma Biln⁴, ¹Augurex Life Sciences Corp, Vancouver, BC, Canada, ²Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ³University of Alberta, Edmonton, AB, Canada, ⁴Augurex Life Sciences, Vancouver, BC, Canada
Background/Purpose: Novel biomarkers for axSpA are urgently needed to enable earlier diagnosis and improve patient outcomes. An assay for quantifying 14-3-3η autoantibodies (AAbs) has been…
Abstract Number: 0849 • ACR Convergence 2025
Mortality and Major Adverse Cardiac Events (MACE) with GLP-1 Receptor Agonists in Psoriatic Arthritis
Nanuka Tsibadze¹, Irakli Tskhakaia¹ and Irene Tan², ¹Jefferson Health - Einstein, Philadelphia, PA, ²Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: Glucagon-like-peptide-1 receptor agonists (GLP-1 RAs) are the novel drug class that has gained widespread attention for its cardiovascular, renal and weight loss benefits in…
Abstract Number: 0747 • ACR Convergence 2025
Patterns of Macrophage Polarization Induced by Serum from Patients with Giant Cell Arteritis and Takayasu’s Arteritis
Irene Carrión-Barberà¹, Ryan D. Stultz², David Cuthbertson³, Nader Khalidi⁴, Curry Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Kenneth Warrington¹², Peter Merkel⁷ and Christian Lood¹³, ¹Department of Rheumatology. Hospital del Mar, Barcelona, Spain, ²University of Washington, Division of Rheumatology, Seattle, WA, ³University of South Florida, Tampa, ⁴Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Pennsylvania, Philadelphia, PA, ⁸VA Boston Healthcare System, Boston, MA, ⁹University of Colorado, Denver, CO, ¹⁰Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, ROCHESTER, MN, ¹³University of Washington, Division of Rheumatology, Seattle
Background/Purpose: Macrophages play a central role in the pathogenesis of large-vessel vasculitides, including giant cell arteritis (GCA) and Takayasu’s arteritis (TAK). Characterizing patterns of macrophage…
Abstract Number: 0863 • ACR Convergence 2025
Myeloid Dendritic Cell Subsets Characterize Muscle of Inclusion Body Myositis Patients and Correlate with KLRG1+ and TBX21+ CD8+ T cells
Raphael Kirou¹, Iago Pinal-Fernandez¹, Maria Casal-Dominguez¹, Katherine Pak¹, Chiseko Ikenaga², Christopher Nelke³, Stefania Dell'orso¹, Faiza Naz¹, Shamima Islam¹, Gustavo Gutierrez-Cruz¹, Werner Stenzel⁴, Albert Selva-O'Callaghan⁵, José Milisenda⁶ and Andrew Mammen⁷, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²The University of Tokyo, Tokyo, Japan, ³Heinrich Heine University of Düsseldorf, Düsseldorf, Germany, ⁴Charite University, Berlin, Germany, ⁵Hospital Universitari Vall d'Hebron, Barcelona, Spain, ⁶Hospital Clinic de Barcelona, Barcelona, Spain, ⁷NIH, Bethesda, MD
Background/Purpose: Although inclusion body myositis (IBM) is an inflammatory myopathy, there are no effective immunomodulating agents, underlying the need for better understanding of its pathogenesis.…
Abstract Number: 0785 • ACR Convergence 2025
It Takes a Community: Exploring the Importance of Community-Level Social Determinants of Health in Total Knee Arthroplasty Outcomes
Chloe Heiting¹, Yiyuan Wu², Susan Goodman³, Peter Sculco⁴, Fei Wang², Rich Caruana⁵, Peter Cram⁶, Said Ibrahim⁷ and Bella Mehta⁸, ¹Northwell Health, New Hyde Park, NY, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery, New York, NY, ⁵Microsoft, Redmond, WA, ⁶University of Maryland School of Medicine, Baltimore, MD, ⁷Thomas Jefferson University, Philadelphia, PA, ⁸Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ
Background/Purpose: Despite changing trends and increased utilization of total knee arthroplasty (TKA) in the United States,1 there are still prominent racial and ethnic disparities in…
Abstract Number: 0847 • ACR Convergence 2025
Interferon Score Effectively Stratifies for Time to Clinically Significant Event Accrual in Systemic Sclerosis Independently of Cutaneous Subset
Stefano Di Donato¹, Rebecca Ross², Marco Minerba³, Vishal Kakkar⁴, Enrico De Lorenzis⁵, Philip Yee⁶, Christopher Denton⁷ and Francesco Del Galdo⁴, ¹University of Leeds, Canosa Sannita, Chieti, Italy, ²Medicine and Health, University of Leeds, Leeds, United Kingdom, ³Campus Bio-Medico University of Rome, Taranto, Taranto, Italy, ⁴University of Leeds, Leeds, United Kingdom, ⁵Catholic University of the Sacred Heart, Roma, Rome, Italy, ⁶UCL, London, United Kingdom, ⁷University College London, UK, London, United Kingdom
Background/Purpose: Systemic Sclerosis (SSc) is a heterogeneous autoimmune disease characterized by vascular damage, immune dysregulation, and fibrosis. It is typically classified into limited cutaneous (lcSSc)…
Abstract Number: 0875 • ACR Convergence 2025
Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-Inhibitor), in Adolescents With Moderate-to-Severe Plaque Psoriasis: Subgroup Analyses From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ICONIC-LEAD)
Lawrence Eichenfield¹, Ricardo Galimberti², Adelaide Hebert³, Wen-Hui Wang⁴, Jennifer Soung⁵, Nina Magnolo⁶, John Browning⁷, Angela Moore⁸, Mark Lebwohl⁹, Dagmar Wilsmann-Theis¹⁰, Joseph F Merola¹¹, Georgios Kokolakis¹², Dariusch Mortazawi¹³, Parbeer Grewal¹⁴, Megan Miller¹⁵, Joseph Cafone¹⁶, Shu Li¹⁷, Gigi Jiang¹⁷, Fabio Nunes¹⁷, Cynthia DeKlotz¹⁸ and Amy Paller¹⁹, ¹University of California, San Diego School of Medicine, La Jolla, CA, USA, La Jolla, CA, ²Hosp Italiano de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, ³University of Texas Medical School-Houston, Bellaire, TX, USA, Bellaire, TX, ⁴Peking University Third Hospital, Haidian District, Beijing, China, Beijing, China (People's Republic), ⁵Southern California Dermatology, Inc, Santa Ana, CA, USA, Santa Ana, ⁶University Hospital Muenster, Muenster, Germany, Muenster, Germany, ⁷Methodist Children's Hospital, San Antonio, TX, USA, San Antonio, TX, ⁸Baylor University Medical Center, Dallas, TX, USA, Dallas, TX, ⁹Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰University Hospital Bonn, Center for Skin Diseases, Bonn, Germany, Bonn, Germany, ¹¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ¹²Charité-Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ¹³Clinical Research Center, Remscheid, Germany, Remscheid, Germany, ¹⁴University of Alberta, Edmonton, Alberta, Canada, Edmonton, AB, Canada, ¹⁵Johnson & Johnson, San Diego, CA, USA, San Diego, CA,, CA, ¹⁶Johnson & Johnson, San Diego, CA, USA, San Diego, CA, CA, ¹⁷Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ¹⁸Johnson & Johnson, San Diego, CA, USA, San Diego, CA, ¹⁹Northwestern University Feinberg School of Medicine, Chicago, IL, USA, Chicago, IL
Background/Purpose: Icotrokinra (ICO), a novel targeted oral peptide, binds the interleukin (IL)-23 receptor to inhibit IL-23 signaling. ICONIC-LEAD (NCT06095115) is the first Phase 3 study…
Abstract Number: 0758 • ACR Convergence 2025
Association Between Baseline IL-6 Levels and the Clinical Phenotype of Giant Cell Arteritis
Raquel Ugena-García¹, Clara Churtichaga Domenech², Judith Vidal-Ripoll², Francina salabert-Carreras², Cristina Calomarde-Gómez¹, Cristina Rocamora-Gisbert³, Irene Peralta-García⁴, Niccolo Viveros², Anne Riveros Frutos³, Ivette Casafont-Solé¹ and Judit Font-Urgelles¹, ¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Germans Trias i Pujol, Barcelona, ³Hospital Germans Trias i Pujol, Barcelona, Spain, ⁴Karolinska Institutet, Clinical Epidemiology Division, Department of Medicine Solna. Karolinska University Hospital, Medical Unit of Gastroenterology, Dermatology, Rheumatology. Theme Inflammation and Ageing, Stockholm, Sweden
Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis in patients over the age of 50. Interleukin-6 (IL-6) has been shown to…
Abstract Number: 0796 • ACR Convergence 2025
Deciphering Synovial Fluid Immune Dysregulation in Rheumatoid Arthritis through Cytokine Profiling and Single-Cell Transcriptomics
Manon LESTURGIE-TALAREK¹, Francesco Carbone², Virginie Gonzalez³, Adrien Schvartz², Sophie Hecquet⁴, Fiona Oudart⁵, Marion Thomas⁶, Roberto D'Alessandro⁷, Yannick Allanore⁸, Mickael Menager² and Jérôme AVOUAC⁹, ¹Paris University, Paris, France, ²Institut Imagine, Paris, ³INSERMU¹⁰¹⁶, Paris, France, ⁴Cochin Hospital, Paris, France, ⁵APHP - Cochin hospital, Paris, France, ⁶APHP, Paris, France, ⁷Cochin Hospital, Paris, ⁸Université Paris Cité, Paris, France, ⁹Rheumatology department, Cochin hospital, Paris, France
Background/Purpose: Rheumatoid arthritis (RA) is driven by complex inflammatory pathways involving immune cell infiltration into synovial tissue and fluid. Synovial fluid (SF) provides direct insight…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].